Riskpilot← Back to searchSign inGet full accessNORBECK ENT AS
ASActiveOrg 994390902Røtveivegen 19, 7340 OppdalConstruction of residential and non-residential buildings · NACE 4100Est. 20095 employees
Revenue 2024
NOK 9,1M
-8% vs 2023
EBITDA margin
12.3%
+64% vs 2023
Equity ratio
4.1%
Financial strength
Net profit 2024
NOK 305K
+223% vs 2023
| Revenue | NOK 9,1M | -8% |
| EBITDA | NOK 1,1M | +64% |
| Net profit | NOK 305K | +223% |
| Total assets | NOK 7,8M | +17% |
| Equity | NOK 322K | +1751% |
| Employees | 5 | — |
Legal name
NORBECK ENT AS
Org number
994390902
Legal form
Aksjeselskap
NACE code
4100 · Construction of residential and non-residential buildings
Founded
10. august 2009
Share capital
NOK 100 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Bygge- og anleggsvirksomhet, eiendomsutvikling samt andre forretningsområder som naturlig faller sammen med dette.
Address
Røtveivegen 19, 7340 Oppdal
Phone
+4741547577
Email
post@norbeckent.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 8 480 | 8 898 | 9 667 | 9 904 | 9 108 |
| Staff expenses | −2 400 | −3 333 | −3 321 | −3 746 | −2 669 |
| EBITDA | 703 | −102 | 578 | 684 | 1 123 |
| Depreciation & amort. | −38 | −147 | −269 | −405 | −259 |
| EBIT | 665 | −250 | 309 | 279 | 864 |
| Net financials | −133 | −239 | −362 | −528 | −560 |
| Profit before tax | 532 | −488 | −53 | −248 | 305 |
| Tax | 117 | −5 | −0 | −0 | −0 |
| Net profit | 415 | −484 | −53 | −248 | 305 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 384 | 6 104 | 7 064 | 6 663 | 7 817 |
| Equity | 802 | 319 | 266 | 17 | 322 |
| Long-term debt | 372 | 3 615 | 4 565 | 4 706 | 5 060 |
| Short-term debt | 3 209 | 2 170 | 2 234 | 1 940 | 2 435 |
| Total debt | 3 582 | 5 786 | 6 799 | 6 646 | 7 495 |
EBITDA margin
12.3%
This company
15.8%
Market median
-22% vs market
20202024
Equity ratio
4.1%
This company
38.2%
Market median
-89% vs market
20202024
Return on equity
94.6%
This company
18.4%
Market median
+414% vs market
20202024
Net profit margin
3.3%
This company
8.1%
Market median
-59% vs market
20202024
Asset turnover
1.17×
This company
1.12×
Market median
+4% vs market
20202024
Debt / equity
23.27×
This company
0.62×
Market median
-3653% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
FR Chief Executive Officer | Chief Executive Officer | 2009 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Former (2) | ||
| Board of Directors | 2009 – 2022 | |
| Board of Directors | 2009 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 25% | 25% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ravo Utvikling As
NORBECK ENT AS Board members of NORBECK ENT AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Frode Rogogjerd Norbeck | Chief Executive Officer | 0 companies |
| Ingebrigt Hevle | Board of Directors | 0 companies |
| Kirsti Rogogjerd Norbeck | Chairman | 0 companies |
| Hallgrim Norbeck | Board of Directors | 0 companies |
| Ovar Ottesen | Board of Directors | 0 companies |
| Per Martin Foss | Board of Directors | 0 companies |